Utility of Aripiprazole in the Treatment of Anorexia Nervosa in Children and Adolescents: A Retrospective,Descriptive,Matched Cohort Study

Abstract

Objective:

Current standards for treatment of anorexia nervosa (AN) in children and adolescents include Family-Based Treatment and nutrition restoration. The use of aripiprazole for AN has been detailed through case series and one retrospective review analyzing the change in outcomes on body mass index and weight restoration. The goal of this descriptive study was to evaluate the impact of aripiprazole on food avoidant behaviors (FABs) and to describe prescribing patterns, including dosing and tolerability.

Methods:

This was a retrospective, descriptive, matched, cohort study of pediatric patients with AN admitted to an eating disorders program (EDP) between January 1, 2018, and December 31, 2023. Patients were included in this study if they had a diagnosis of AN and were started on aripiprazole for eating disorder cognitions. Patients were matched 1:2 to a control group based on age, sex, and length of stay.

Results:

A total of 42 patients on aripiprazole were analyzed and matched to 84 controls. Aripiprazole was associated with a reduction in FABs with a mean change over the evaluated time period of 3.5 versus 0.9 (p = 0.026). The mean starting dose of aripiprazole was 1.9 mg/day, with a mean discharge dose of 2.8 mg/day. Aripiprazole was overall well-tolerated.

Conclusion:

Aripiprazole was associated with an improvement in FABs among children and adolescents admitted to an EDP. Additionally, low-dose aripiprazole improved weight, likelihood of achieving target weight, and was well-tolerated.

Get full access to this article

View all access options for this article.

References

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision. Fifth. American Psychiatric Association: Washington, DC; 2022.

Attia

, Kaplan

, Walsh

, et al. Olanzapine versus Placebo for Out-Patients with Anorexia Nervosa. Psychol Med, 2011; 41(10):2177–2182; doi: 10.1017/S0033291711000390

Attia

, Steinglass

, Walsh

, et al. Olanzapine versus placebo in adult outpatients with anorexia nervosa: A randomized clinical trial. Am J Psychiatry, 2019; 176(6):449–456; doi: 10.1176/appi.ajp.2018.18101125

Bissada

, Tasca

, Barber

, et al. Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: A randomized, double-blind, placebo-controlled trial. Am J Psychiatry, 2008; 165(10):1281–1288; doi: 10.1176/appi.ajp.2008.07121900

Brambilla

, Garcia

, Fassino

, et al. Olanzapine therapy in anorexia nervosa: Psychobiological effects. Int Clin Psychopharmacol, 2007a;22(4):197–204; doi: 10.1097/YIC.0b013e328080ca31

Brambilla

, Monteleone

, Maj

. Olanzapine-Induced weight gain in anorexia nervosa: Involvement of leptin and ghrelin secretion? Psychoneuroendocrinology, 2007b;32(4):402–406; doi: 10.1016/j.psyneuen.2007.02.005

Chiu

H-P

, Huang

M-W

, Tsai

S-Y

, et al. A retrospective study of pharmacological treatment in anorexia nervosa: 6-Month and 12-Month Follow-Up. BMC Psychiatry, 2023; 23(1):126; doi: 10.1186/s12888-023-04604-3

Couturier

, Isserlin

, Norris

, et al. Canadian practice guidelines for the treatment of children and adolescents with eating disorders. J Eat Disord, 2020; 8(1):4; doi: 10.1186/s40337-020-0277-8

Couturier

, Isserlin

, Spettigue

, et al. Psychotropic medication for children and adolescents with eating disorders. Child Adolesc Psychiatr Clin N Am, 2019; 28(4):583–592; doi: 10.1016/j.chc.2019.05.005

10.

Crone

, Fochtmann

, Attia

, et al. The American Psychiatric Association practice guideline for the treatment of patients with eating disorders. Am J Psychiatry, 2023; 180(2):167–171; doi: 10.1176/appi.ajp.23180001

11.

de Bartolomeis

, Tomasetti

, Iasevoli

. Update on the mechanism of action of aripiprazole: Translational insights into antipsychotic strategies beyond dopamine receptor antagonism. CNS Drugs, 2015; 29(9):773–799; doi: 10.1007/s40263-015-0278-3

12.

Findling

, Kauffman

, Sallee

, et al. Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders: An open-label, dose-escalation study. J Clin Psychopharmacol, 2008; 28(4):441–446; doi: 10.1097/JCP.0b013e31817dd520

13.

Frank

GKW

. Aripiprazole, a partial dopamine agonist to improve adolescent anorexia nervosa-a case series: Aripiprazole in adolescent anorexia nervosa. Int J Eat Disord, 2016; 49(5):529–533; doi: 10.1002/eat.22485

14.

Frank

, Arnold

, Jaite

, et al. Antipsychotic effects on anthropometric outcomes in anorexia nervosa: A retrospective chart review of hospitalized children and adolescents. J Eat Disord, 2023; 11(1):151; doi: 10.1186/s40337-023-00862-4

15.

Frank

GKW

, Shott

, DeGuzman

. The neurobiology of eating disorders. Child Adolesc Psychiatr Clin N Am, 2019; 28(4):629–640; doi: 10.1016/j.chc.2019.05.007

16.

Frank

GKW

, Shott

, Hagman

, et al. The partial dopamine D2 receptor agonist aripiprazole is associated with weight gain in adolescent anorexia nervosa. Int J Eat Disord, 2017; 50(4):447–450; doi: 10.1002/eat.22704

17.

Hagman

. Validation of the Ease of Eating Scale. 2006.

18.

Hagman

, Gralla

, Sigel

, et al. A double-blind, placebo-controlled study of risperidone for the treatment of adolescents and young adults with anorexia nervosa: A pilot study. J Am Acad Child Adolesc Psychiatry, 2011; 50(9):915–924; doi: 10.1016/j.jaac.2011.06.009

19.

Harrington

, Jimerson

, Haxton

, et al. Initial evaluation, diagnosis, and treatment of anorexia nervosa and bulimia nervosa. Am Fam Physician, 2015; 91(1):46–52.

20.

Hornberger

, Lane

, The Committee On Adolescence . Identification and management of eating disorders in children and adolescents. Pediatrics, 2021; 147(1):e2020040279; doi: 10.1542/peds.2020-040279

21.

Kafantaris

, Leigh

, Hertz

, et al. A placebo-controlled pilot study of adjunctive olanzapine for adolescents with anorexia nervosa. J Child Adolesc Psychopharmacol, 2011; 21(3):207–212; doi: 10.1089/cap.2010.0139

22.

Lock

. Updates on treatments for adolescent anorexia nervosa. Child Adolesc Psychiatr Clin N Am, 2019; 28(4):523–535; doi: 10.1016/j.chc.2019.05.001

23.

Marzola

, Desedime

, Giovannone

, et al. Atypical antipsychotics as augmentation therapy in anorexia nervosa. PLoS One, 2015; 10(4):e0125569; doi: 10.1371/journal.pone.0125569

24.

Mondraty

, Birmingham

, Touyz

, et al. Randomized controlled trial of olanzapine in the treatment of cognitions in anorexia nervosa. Australas Psychiatry, 2005; 13(1):72–75; doi: 10.1080/j.1440-1665.2004.02154.x

25.

Mysliwiec

. Neuroscience of adolescent anorexia nervosa: Implications for Family-Based Treatment (FBT). Front Psychiatry, 2020; 11:418; doi: 10.3389/fpsyt.2020.00418

26.

Powers

, Klabunde

, Kaye

. Double-Blind placebo-controlled trial of quetiapine in anorexia nervosa. Eur Eat Disord Rev, 2012; 20(4):331–334; doi: 10.1002/erv.2169

27.

Pringsheim

, Panagiotopoulos

, Davidson

, et al.; Canadian Alliance for Monitoring Effectiveness and Safety of Antipsychotics in Children (CAMESA) guideline group. Evidence-Based recommendations for monitoring safety of second-generation antipsychotics in children and youth. Paediatr Child Health, 2011; 16(9):581–589.

28.

Riquin

, Raynal

, Mattar

, et al.; EVHAN group. Is the severity of the clinical expression of anorexia nervosa influenced by an anxiety, depressive, or obsessive-compulsive comorbidity over a lifetime? Front Psychiatry, 2021; 12:658416; doi: 10.3389/fpsyt.2021.658416

29.

Spettigue

, Norris

, Maras

, et al. Evaluation of the effectiveness and safety of olanzapine as an adjunctive treatment for anorexia nervosa in adolescents: An open-label trial. J Can Acad Child Adolesc Psychiatry, 2018; 27(3):197–208.

30.

Tahıllıoğlu

, Özcan

, Yüksel

, et al. Is aripiprazole a key to unlock anorexia nervosa?: A case series. Clin Case Rep, 2020; 8(12):2827–2834; doi: 10.1002/ccr3.3271

31.

Thorey

, Blanchet

, Guessoum

, et al. Efficacy and tolerance of second-generation antipsychotics in anorexia nervosa: A systematic scoping review. PLoS One, 2023; 18(3):e0278189; doi: 10.1371/journal.pone.0278189

32.

Trunko

, Schwartz

, Duvvuri

, et al. Aripiprazole in anorexia nervosa and low-weight bulimia nervosa: Case reports. Int J Eat Disord, 2011; 44(3):269–275; doi: 10.1002/eat.20807

33.

Tuplin

, Holahan

. Aripiprazole, A drug that displays partial agonism and functional selectivity. CN, 2017; 15(8); doi: 10.2174/1570159X15666170413115754

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.33 MB